In-silico analysis of riboswitch of Nocardia farcinica for design of its inhibitors and pharmacophores
by Amritpreet Kaur; Somdutt Mujwar; Neeru Adlakha
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 9, No. 3, 2016

Abstract: Nocardia farcinica causes human infections either by pulmonary inhalation or inoculation via wounds and causes nocardiosis, brain abscesses and secondary infection in immune-compromised patients. N. farcinica infection is mostly reported in Asia, Europe and North America with a mortality rate of 10-31%. Antibiotic treatment available for N. farcinica infection have the problem of side-effects and drug resistance development by bacteria against antibiotics such as ampicillin, third- generation cephalosporins, etc. Therefore, this paper explored riboswitch as an alternative drug-target to address these issues and its optimal inhibitors are designed. Riboswitches are regulatory elements found in the 5′UTRs of many mRNAs. The designed lead molecule will prove helpful in the development of newer drug molecules for the infection treatment caused by N. farcinica. The proposed inhibitors are supposed to be free from the problem of side-effects and drug-resistance associated with antibiotics, as there are remote chances of mutations in riboswitches.

Online publication date: Sun, 14-Aug-2016

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com